Translating groundbreaking science into tomorrow’s cures

Explore our science

Pioneering the future of genomic medicine

Sangamo uses its deep scientific expertise and proprietary zinc finger technology to create genomic cures for patients suffering from severe diseases for which today’s medicine can only offer symptom management at best.

Explore our pipeline

Explore our latest corporate presentation by clicking below to stay informed and gain valuable insights into our company’s vision, achievements, and roadmap.

View the corporate presentation

The Latest at Sangamo

News

Presentations

All Presentations

Publications

All Publications

Company pipeline and business development opportunities

Clinical Trials

CORE NEUROLOGY PIPELINE
Indication	Preclinical	Phase 1/2	Pivotal	Partner	Commentary
Chronic Neuropathic Pain (Nav 1.7)	Data presented at ASGCT 23			None	Nav 1.7 IND-enabling activities continue to advance
Prion Disease	Data presented at ASGCT 24			None	Prion CTA-enabling activities continue to advance
Tauopathies	Data presented at ASGCT 24			Genentech	August 2024: Announced epigenetic regulation and capsid delivery license agreement with Genentech
Undisclosed				Genentech	August 2024: Announced epigenetic regulation and capsid delivery license agreement with Genentech
ALS/FTD	Data presented at ASGCT 24			Alexion	None
Huntington's Disease				Takeda	None

OTHER PROGRAMS
Indication	Preclinical	Phase 1/2	Pivotal	Partner	Commentary
Hemophilia A (Giroctogene fitelparvovec)	Data presented at ASH 2023			Pfizer	July 2024: Positive topline readout in Phase 3 AFFINE trial. Pfizer plans to discuss data with regulatory authorities in coming months.
Fabry Disease (Isaralgagene civaparvovec)	Data presented at WORLDSymposium 2024			None	Continue to amass encouraging clinical data. Potential partnership discussions ongoing.